Uniplan Investment Counsel’s Collegium Pharmaceutical COLL Stock Holding History

Uniplan Investment Counsel’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.27M	Sell	68,747 -42,992	-38%	-$1.82M	0.23%	96
2025 Q4	$5.17M	Sell	111,739 -289	-0.3%	-$12.1K	0.52%	54
2025 Q3	$3.92M	Sell	112,028 -18,397	-14%	-$640K	0.38%	67
2025 Q2	$3.86M	Sell	130,425 -12,376	-9%	-$353K	0.39%	62
2025 Q1	$4.26M	Buy	142,801 +797	+0.6%	+$24.4K	0.41%	61
2024 Q4	$4.07M	Sell	142,004 -1,880	-1%	-$62.2K	0.38%	69
2024 Q3	$5.56M	Sell	143,884 -2,491	-2%	-$88.8K	0.49%	51
2024 Q2	$4.71M	Sell	146,375 -543	-0.4%	-$18.8K	0.43%	57
2024 Q1	$5.7M	Sell	146,918 -175	-0.1%	-$6.12K	0.45%	53
2023 Q4	$4.53M	Buy	147,093 +44,477	+43%	+$1.11M	0.34%	63
2023 Q3	$2.32M	Buy	+102,616	New	+$2.34M	0.18%	98

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Uniplan Investment Counsel's COLL Position: Q1 2026 in Review

Uniplan Investment Counsel reduced its Collegium Pharmaceutical (COLL) stake by 38% in Q1 2026, selling an estimated $1.82M and leaving 68,747 shares worth $2.27M. The position accounts for 0.23% of the portfolio, ranked #96.

Uniplan Investment Counsel first reported a position in COLL in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.7M in Q1 2024. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

Uniplan Investment Counsel held 68,747 shares of Collegium Pharmaceutical worth $2.27M as of Q1 2026.
Uniplan Investment Counsel sold 42,992 Collegium Pharmaceutical shares in Q1 2026, an estimated $1.82M.
Collegium Pharmaceutical made up 0.23% of Uniplan Investment Counsel's portfolio in Q1 2026, its #96 holding.
Uniplan Investment Counsel first reported a position in Collegium Pharmaceutical in Q3 2023 and has held it in 11 quarters since.
Uniplan Investment Counsel's Collegium Pharmaceutical position peaked at $5.7M in Q1 2024.
266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Uniplan Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.